Atherotech Diagnostics Lab bolsters Research efforts with addition of Abate as Chief Clinical Officer
BIRMINGHAM, Ala.-- Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, announces the addition of Gerard Abate, M.D., as the company’s Chief Clinical Officer.
Abate is responsible for expanding awareness of the company’s patented VAP+® Lipid Panel and its clinical utility in cardiometabolic research. He will work with Atherotech’s distinguished Medical Advisory Board and field of Medical Science Consultants to help clinicians better understand cardiovascular risk reduction and deliver personalized treatment strategies to improve health outcomes.
“Jerry has vast experience in developing strategic relationships with key thought leaders in academics as well as relationships with key medical societies,” CEO Michael Mullen said. “He understands the power of preventive cardiovascular medicine and the role it plays in accurately stratifying risk.”
Abate spent 14 years as a non-invasive clinical cardiologist and owner of Williamsburg Cardiology in Williamsburg, Va. As a specialist in consultative cardiology focused on heart failure and lipidology, he became an early adopter in the utilization of advanced lipid assessments.
In 2004, Abate left his practice for work in the pharmaceutical industry supporting various cardiovascular products. He most recently served as Senior Medical Director for Thrombosis in Medical Affairs at Daiichi Sankyo. He played a key role in the development and execution of the medical strategy for the upcoming launch of Daiichi Sankyo’s oral anticoagulant edoxaban and oversaw the communications and clinical trial strategy for the company’s Effient® antiplatelet agent.
Throughout his career in the pharmaceutical industry, Abate brought forth product advancements and process improvements to the medical affairs departments he worked in. He was instrumental in revising the investigator-initiated trial process at Sanofi Aventis and brought automation to several companies, improving efficiency, compliance and controlling budgets. During his time with Amarin Pharma Inc., he built all medical affairs functions and was responsible for the startup of the 8,000-patient REDUCE-IT cardiovascular outcomes trial for the drug Vascepa®.
“Jerry will foster our relationships within the pharmaceutical industry as well as lead our strategic research collaborations, including the recent partnership with Johns Hopkins Ciccarone Center for the Prevention of Heart Disease,” Mullen said. “He brings the energy and intelligence that are instrumental in keeping the momentum in these latest research initiatives.”
For information on Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510 . Health care professionals interested in real patient cases and lipidology commentary may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.
About Atherotech Diagnostics Lab & the VAP®+ Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy HeartTM, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com.